GlassScriptPhysician profile
Joseph Marshalek
NPI 1477180016
$1,828.44
in general payments reported to CMS, 2019-2025
27 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.25 · 2022: $26.83 · 2024: $734 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.19 |
| Education | $290.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $260.27 | 2024-2025 | Rybrevant, Erleada, Akeega |
| E.R. Squibb & Sons, L.L.C. | $234.84 | 2024-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $165.21 | 2024-2025 | Lynparza, Enhertu, Tagrisso |
| Astellas Pharma US INC | $133.22 | 2024-2025 | Xospata |
| Lilly USA, LLC | $90.19 | 2025 | |
| Emd Serono, INC. | $89.16 | 2024 | |
| Daiichi Sankyo INC. | $80.29 | 2024-2025 | Enhertu, Datroway |
| Beone Medicines USA, INC. | $62.97 | 2025 | Tevimbra, Brukinsa |
| Celgene Corporation | $60.76 | 2024-2025 | Reblozyl |
| Adc Therapeutics America, INC. | $60.50 | 2024-2025 | |
| Genzyme Corporation | $57.26 | 2024 | |
| Springworks Therapeutics, INC. | $56.19 | 2024-2025 | Ogsiveo |
| Incyte Corporation | $53.71 | 2025 | Jakafi, Monjuvi, Zynyz |
| Exelixis INC. | $50.75 | 2021-2024 | Cabometyx |
| Abbvie INC. | $49.57 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $38.61 | 2024 | |
| Genentech USA, INC. | $34.28 | 2024 | Polivy |
| Jazz Pharmaceuticals INC. | $30.90 | 2024 | |
| Pharmaessentia USA Corporation | $30.77 | 2025 | Besremi |
| Beigene USA, INC. | $28.72 | 2024 | Brukinsa |
| Aurinia Pharma U.S., INC. | $26.83 | 2022 | |
| Deciphera Pharmaceuticals INC. | $25.78 | 2024 | Qinlock |
| Geron Corporation | $23.89 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $23.19 | 2024 | Ayvakit |
| Kyowa Kirin, INC. | $20.52 | 2025 | |
| Pfizer INC. | $20.18 | 2024 | |
| Mirati Therapeutics, INC. | $19.88 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Marshalek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.